메뉴 건너뛰기




Volumn 3, Issue 5, 2015, Pages 436-443

The interplay of immunotherapy and chemotherapy: Harnessing potential synergies

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; CISPLATIN; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; GAMMA INTERFERON INDUCIBLE PROTEIN 10; GEMCITABINE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 10; IPILIMUMAB; NIVOLUMAB; PACLITAXEL; PATTERN RECOGNITION RECEPTOR; PEMBROLIZUMAB; TEMOZOLOMIDE; TG 4010; TOLL LIKE RECEPTOR 3; TRANSFORMING GROWTH FACTOR BETA; TUMOR NECROSIS FACTOR ALPHA; ANTINEOPLASTIC AGENT;

EID: 84962205403     PISSN: 23266066     EISSN: 23266074     Source Type: Journal    
DOI: 10.1158/2326-6066.CIR-15-0064     Document Type: Article
Times cited : (640)

References (52)
  • 2
    • 84874108466 scopus 로고    scopus 로고
    • Chemoimmunotherapy: Reengineering tumor immunity
    • Chen G, Emens LA. Chemoimmunotherapy: reengineering tumor immunity. Cancer Immunol Immunother 2013;62:203-16.
    • (2013) Cancer Immunol Immunother , vol.62 , pp. 203-216
    • Chen, G.1    Emens, L.A.2
  • 3
    • 84921737737 scopus 로고    scopus 로고
    • Vaccines for cancer prevention: A practical and feasible approach to the cancer epidemic
    • Finn O. Vaccines for cancer prevention: a practical and feasible approach to the cancer epidemic. Cancer Immunol Res 2014;2:708-13.
    • (2014) Cancer Immunol Res , vol.2 , pp. 708-713
    • Finn, O.1
  • 4
    • 84860188105 scopus 로고    scopus 로고
    • Therapeutic cancer vaccines: Current status and moving forward
    • Schlom J. Therapeutic cancer vaccines: current status and moving forward. J Natl Cancer Inst 2012;104:599-613.
    • (2012) J Natl Cancer Inst , vol.104 , pp. 599-613
    • Schlom, J.1
  • 5
    • 84858766182 scopus 로고    scopus 로고
    • The blockade of immune checkpoints in cancer therapy
    • Pardoll DM The blockade of immune checkpoints in cancer therapy. Nat Rev Cancer 2012;12:252-64.
    • (2012) Nat Rev Cancer , vol.12 , pp. 252-264
    • Pardoll, D.M.1
  • 6
    • 84927150740 scopus 로고    scopus 로고
    • Immune checkpoint blockade in cancer therapy
    • Jan 20 Epub ahead of print
    • Postow MA, Callahan MK, Wolchok JD. Immune checkpoint blockade in cancer therapy. J Clin Oncol 2015 Jan 20. pii: JCO.2014.59.4358. [Epub ahead of print.]
    • (2015) J Clin Oncol , vol.59 , pp. 4358
    • Postow, M.A.1    Callahan, M.K.2    Wolchok, J.D.3
  • 8
    • 84894107349 scopus 로고    scopus 로고
    • New insights into cancer immunoediting and its three component phases - Elimination, equilibrium, and escape
    • Mittal D, Gubin MM, Schreiber RD, Smyth MJ. New insights into cancer immunoediting and its three component phases - elimination, equilibrium, and escape. Curr Opin Immunol 2014;27:16-25.
    • (2014) Curr Opin Immunol , vol.27 , pp. 16-25
    • Mittal, D.1    Gubin, M.M.2    Schreiber, R.D.3    Smyth, M.J.4
  • 10
    • 84913586780 scopus 로고    scopus 로고
    • Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy
    • Sistigu A, Yamazaki T, Vacchelli E, Chaba K, Enot DP, Adam J, et al. Cancer cell-autonomous contribution of type I interferon signaling to the efficacy of chemotherapy. Nat Med 2014;20:1301-9.
    • (2014) Nat Med , vol.20 , pp. 1301-1309
    • Sistigu, A.1    Yamazaki, T.2    Vacchelli, E.3    Chaba, K.4    Enot, D.P.5    Adam, J.6
  • 11
    • 84890043669 scopus 로고    scopus 로고
    • Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL4
    • Sukkurwala AQ, Martins I, Wang Y, Schlemmer F, Ruckenstuhl C, Durchschlag M, et al. Immunogenic calreticulin exposure occurs through a phylogenetically conserved stress pathway involving the chemokine CXCL4. Cell Death Differ 2014;21:59-68.
    • (2014) Cell Death Differ , vol.21 , pp. 59-68
    • Sukkurwala, A.Q.1    Martins, I.2    Wang, Y.3    Schlemmer, F.4    Ruckenstuhl, C.5    Durchschlag, M.6
  • 13
    • 34948820602 scopus 로고    scopus 로고
    • Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy
    • Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Tolllike receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med 2007;13:1050-9.
    • (2007) Nat Med , vol.13 , pp. 1050-1059
    • Apetoh, L.1    Ghiringhelli, F.2    Tesniere, A.3    Obeid, M.4    Ortiz, C.5    Criollo, A.6
  • 14
    • 70350569295 scopus 로고    scopus 로고
    • Activation of the NRLP3 inflammasome in dendritic cells induces IL-1-beta-dependent adaptive immunity against tumors
    • Ghiringhelli F, Apetoh L, Tesniere A, Ayeric L, Ma Y, Ortiz C, et al. Activation of the NRLP3 inflammasome in dendritic cells induces IL-1-beta-dependent adaptive immunity against tumors. Nat Med 2009; 15:1170-8.
    • (2009) Nat Med , vol.15 , pp. 1170-1178
    • Ghiringhelli, F.1    Apetoh, L.2    Tesniere, A.3    Ayeric, L.4    Ma, Y.5    Ortiz, C.6
  • 16
    • 80051796334 scopus 로고    scopus 로고
    • Toll-like receptor 4 single-nucleotide polymorphisms asp299gly and thr399ile in head and neck squamous cell carcinomas
    • Bergmann C, Bachmann HS, Bankfalvi A, Lotfi R, Putter C, Wild CA, et al. Toll-like receptor 4 single-nucleotide polymorphisms Asp299Gly and Thr399Ile in head and neck squamous cell carcinomas. J Transl Med 2011;9:139.
    • (2011) J Transl Med , vol.9 , pp. 139
    • Bergmann, C.1    Bachmann, H.S.2    Bankfalvi, A.3    Lotfi, R.4    Putter, C.5    Wild, C.A.6
  • 17
    • 84871356760 scopus 로고    scopus 로고
    • Loss of function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer
    • Vacchelli E, Galluzzi L, Rousseau V, Rigoni A, Tesniere A, Delahaye N, et al. Loss of function alleles of P2RX7 and TLR4 fail to affect the response to chemotherapy in non-small cell lung cancer. Oncoimmunology 2012; 1:271-8.
    • (2012) Oncoimmunology , vol.1 , pp. 271-278
    • Vacchelli, E.1    Galluzzi, L.2    Rousseau, V.3    Rigoni, A.4    Tesniere, A.5    Delahaye, N.6
  • 18
    • 83755181759 scopus 로고    scopus 로고
    • Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice
    • Michaud M, Martins I, Sukkurwala AQ, Adjemian S, Ma Y, Pellegatti P, et al. Autophagy-dependent anticancer immune responses induced by chemotherapeutic agents in mice. Science 2011;334:1573-7.
    • (2011) Science , vol.334 , pp. 1573-1577
    • Michaud, M.1    Martins, I.2    Sukkurwala, A.Q.3    Adjemian, S.4    Ma, Y.5    Pellegatti, P.6
  • 19
    • 84890086459 scopus 로고    scopus 로고
    • Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments
    • Inoue H, Tani K. Multimodal immunogenic cancer cell death as a consequence of anticancer cytotoxic treatments. Cell Death Differ 2014;21:39-49.
    • (2014) Cell Death Differ , vol.21 , pp. 39-49
    • Inoue, H.1    Tani, K.2
  • 20
    • 84892942936 scopus 로고    scopus 로고
    • CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy
    • Ma Y, Mattarollo SR, Adjemian S, Yang H, Aymeric L, Hannani D, et al. CCL2/CCR2-dependent recruitment of functional antigen-presenting cells into tumors upon chemotherapy. Cancer Res 2014;74:436-45.
    • (2014) Cancer Res , vol.74 , pp. 436-445
    • Ma, Y.1    Mattarollo, S.R.2    Adjemian, S.3    Yang, H.4    Aymeric, L.5    Hannani, D.6
  • 21
    • 0038326676 scopus 로고    scopus 로고
    • Induction of tumor cell apoptosis in vivo increases tumor antigen crosspresentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells
    • Nowak AK, Lake RA, Marzo AL, Scott B, Heath WR, Collins EJ, et al. Induction of tumor cell apoptosis in vivo increases tumor antigen crosspresentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol 2003;170:4905-13.
    • (2003) J Immunol , vol.170 , pp. 4905-4913
    • Nowak, A.K.1    Lake, R.A.2    Marzo, A.L.3    Scott, B.4    Heath, W.R.5    Collins, E.J.6
  • 22
    • 84920982588 scopus 로고    scopus 로고
    • Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy
    • McDonnell AM, Lesterhuis WJ, Khong A, Nowak AK, Lake RA, Currie AJ, et al. Tumor-infiltrating dendritic cells exhibit defective cross-presentation of tumor antigens, but is reversed by chemotherapy. Eur J Immunol 2015;45:49-59.
    • (2015) Eur J Immunol , vol.45 , pp. 49-59
    • McDonnell, A.M.1    Lesterhuis, W.J.2    Khong, A.3    Nowak, A.K.4    Lake, R.A.5    Currie, A.J.6
  • 23
    • 0042591416 scopus 로고    scopus 로고
    • Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors
    • Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res 2003;63:4490-6.
    • (2003) Cancer Res , vol.63 , pp. 4490-4496
    • Nowak, A.K.1    Robinson, B.W.2    Lake, R.A.3
  • 24
    • 78049479930 scopus 로고    scopus 로고
    • Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms
    • Fridlender ZG, Sun J, Singhal S, Kapoor V, Cheng G, Suzuki E, et al. Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms. Mol Ther 2010;18:1947-59.
    • (2010) Mol Ther , vol.18 , pp. 1947-1959
    • Fridlender, Z.G.1    Sun, J.2    Singhal, S.3    Kapoor, V.4    Cheng, G.5    Suzuki, E.6
  • 27
    • 84878849679 scopus 로고    scopus 로고
    • Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma
    • Ghansah T, Vohra N, Kinney K, Weber A, Kodumudi K, Springett G, et al. Dendritic cell immunotherapy combined with gemcitabine chemotherapy enhances survival in a murine model of pancreatic carcinoma. Cancer Immunol Immunother 2013;62:1083-91.
    • (2013) Cancer Immunol Immunother , vol.62 , pp. 1083-1091
    • Ghansah, T.1    Vohra, N.2    Kinney, K.3    Weber, A.4    Kodumudi, K.5    Springett, G.6
  • 28
    • 84903527674 scopus 로고    scopus 로고
    • Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): An open-label, randomized, phase 3 trial
    • Middleton G, Silcocks P, Cox T, Valle J, Wadsley J, Propper D, et al. Gemcitabine and capecitabine with or without telomerase peptide vaccine GV1001 in patients with locally advanced or metastatic pancreatic cancer (TeloVac): an open-label, randomized, phase 3 trial. Lancet Oncol 2014; 15:829-40.
    • (2014) Lancet Oncol , vol.15 , pp. 829-840
    • Middleton, G.1    Silcocks, P.2    Cox, T.3    Valle, J.4    Wadsley, J.5    Propper, D.6
  • 29
    • 77950473925 scopus 로고    scopus 로고
    • Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer
    • Gulley JL, Arlen PM, Madan RA, Tsang KY, Pazdur MP, Skarupa L, et al. Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer. Cancer Immunol Immunother 2010;59:663-74.
    • (2010) Cancer Immunol Immunother , vol.59 , pp. 663-674
    • Gulley, J.L.1    Arlen, P.M.2    Madan, R.A.3    Tsang, K.Y.4    Pazdur, M.P.5    Skarupa, L.6
  • 30
    • 84894488563 scopus 로고    scopus 로고
    • The effects of gemcitabine and capecitabine combination chemotherapy and of low dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patient with advanced pancreatic cancer
    • Annels NE, Shaw VE, Gabitass RF, Billingham L, Corrie P, Eatock M, et al. The effects of gemcitabine and capecitabine combination chemotherapy and of low dose adjuvant GM-CSF on the levels of myeloid-derived suppressor cells in patient with advanced pancreatic cancer. Cancer Immunol Immunother 2014;63:175-83.
    • (2014) Cancer Immunol Immunother , vol.63 , pp. 175-183
    • Annels, N.E.1    Shaw, V.E.2    Gabitass, R.F.3    Billingham, L.4    Corrie, P.5    Eatock, M.6
  • 31
    • 79151486551 scopus 로고    scopus 로고
    • A lethally irradiated allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A phase II trial of safety, efficacy, and immune activation
    • Lutz E, Yeo CJ, Lillemoe KD, Biedrzycki B, Kobrin B, Herman J, et al. A lethally irradiated allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic adenocarcinoma. A Phase II trial of safety, efficacy, and immune activation. Ann Surg 2011;253: 328-35.
    • (2011) Ann Surg , vol.253 , pp. 328-335
    • Lutz, E.1    Yeo, C.J.2    Lillemoe, K.D.3    Biedrzycki, B.4    Kobrin, B.5    Herman, J.6
  • 32
    • 70349926513 scopus 로고    scopus 로고
    • A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. Docetaxel plus prednisone in symptomatic, castrationresistant prostate cancer (CRPC) [abstract]
    • Absrract nr 07
    • Small E, Demkow T, Gerritsen WR, Rolland F, Hoskin P, Smith DC, et al. A phase III trial of GVAX immunotherapy for prostate cancer in combination with docetaxel vs. docetaxel plus prednisone in symptomatic, castrationresistant prostate cancer (CRPC) [abstract]. Presented at the 2009 Genitourinary Cancers Symposium. Absrract nr 07.
    • Presented at the 2009 Genitourinary Cancers Symposium
    • Small, E.1    Demkow, T.2    Gerritsen, W.R.3    Rolland, F.4    Hoskin, P.5    Smith, D.C.6
  • 33
    • 79151482353 scopus 로고    scopus 로고
    • GM-CSF-secreting vaccines for solid tumors: Moving forward
    • Gupta R, Emens LA. GM-CSF-secreting vaccines for solid tumors: moving forward. Discov Med 2010;10:52-60.
    • (2010) Discov Med , vol.10 , pp. 52-60
    • Gupta, R.1    Emens, L.A.2
  • 34
    • 77956680680 scopus 로고    scopus 로고
    • A novel chemoimmunomodulating property of docetaxel: Suppression of myeloid-derived suppressor cells in tumor bearers
    • Kodumudi KN, Woan K, Gilvary DL, Sahakian E, Wei S, Djeu JY. A novel chemoimmunomodulating property of docetaxel: suppression of myeloid-derived suppressor cells in tumor bearers. Clin Cancer Res 2010;16: 4583-94.
    • (2010) Clin Cancer Res , vol.16 , pp. 4583-4594
    • Kodumudi, K.N.1    Woan, K.2    Gilvary, D.L.3    Sahakian, E.4    Wei, S.5    Djeu, J.Y.6
  • 35
    • 84878016733 scopus 로고    scopus 로고
    • Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death
    • Hodge JW, Garnett CT, Farsaci B, Palena C, Tsang KY, Ferrone S, et al. Chemotherapy-induced immunogenic modulation of tumor cells enhances killing by cytotoxic T lymphocytes and is distinct from immunogenic cell death. Int J Cancer 2013;133:624-36.
    • (2013) Int J Cancer , vol.133 , pp. 624-636
    • Hodge, J.W.1    Garnett, C.T.2    Farsaci, B.3    Palena, C.4    Tsang, K.Y.5    Ferrone, S.6
  • 36
    • 51049083164 scopus 로고    scopus 로고
    • Combination chemotherapy and ALVA-CEA/B7.1 vaccine in patients with metastatic colorectal cancer
    • Kaufman HL, Lenz HJ, Marshall J, Singh D, Garett C, Cripps C, et al. Combination chemotherapy and ALVA-CEA/B7.1 vaccine in patients with metastatic colorectal cancer. Clin Cancer Res 2008;14:4843-9.
    • (2008) Clin Cancer Res , vol.14 , pp. 4843-4849
    • Kaufman, H.L.1    Lenz, H.J.2    Marshall, J.3    Singh, D.4    Garett, C.5    Cripps, C.6
  • 37
    • 84943746201 scopus 로고    scopus 로고
    • TIME, a phase 2b/3 study evaluating TG4010incombination withfirst line therapy in advanced non small cell lung cancer (NSCLC). Phase 2b results
    • Quoix E, Loxonczy G, Forget F, Chouaid C, Papai Z, Gervais R, et al. TIME, a phase 2b/3 study evaluating TG4010incombination withfirst line therapy in advanced non small cell lung cancer (NSCLC). Phase 2b results. Ann Oncol 2014;25(suppl. 4):iv361-iv372.
    • (2014) Ann Oncol , vol.25 , pp. iv361-iv372
    • Quoix, E.1    Loxonczy, G.2    Forget, F.3    Chouaid, C.4    Papai, Z.5    Gervais, R.6
  • 38
    • 79959772576 scopus 로고    scopus 로고
    • Ipilimumab plus dacarbazine for previously untreated metastatic melanoma
    • Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med 2011;364:2517-26.
    • (2011) N Engl J Med , vol.364 , pp. 2517-2526
    • Robert, C.1    Thomas, L.2    Bondarenko, I.3    O'Day, S.4    Weber, J.5    Garbe, C.6
  • 39
    • 84867619829 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy treatment in stage IIIB/IV non-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase II study
    • Lynch TJ, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study. J Clin Oncol 2012;30:3654.
    • (2012) J Clin Oncol , vol.30 , pp. 3654
    • Lynch, T.J.1    Bondarenko, I.2    Luft, A.3    Serwatowski, P.4    Barlesi, F.5    Chacko, R.6
  • 40
    • 84871532643 scopus 로고    scopus 로고
    • Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: Results from a randomized, double-blind, multicenter phase 2 trial
    • Reck M, Bondarenko I, Luft A, Serwatowski P, Barlesi F, Chacko R, et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial. Ann Oncol 2013;24:75-83.
    • (2013) Ann Oncol , vol.24 , pp. 75-83
    • Reck, M.1    Bondarenko, I.2    Luft, A.3    Serwatowski, P.4    Barlesi, F.5    Chacko, R.6
  • 41
    • 77955487541 scopus 로고    scopus 로고
    • Firstline chemoimmunotherapy in metastatic breast carcinoma: Combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity
    • Brignone C, Gutierrez M, Mefti F, Brain E, Jarcau R, Cvitkovic F, et al. Firstline chemoimmunotherapy in metastatic breast carcinoma: combination of paclitaxel and IMP321 (LAG-3Ig) enhances immune responses and antitumor activity. J Transl Med 2010;8:71.
    • (2010) J Transl Med , vol.8 , pp. 71
    • Brignone, C.1    Gutierrez, M.2    Mefti, F.3    Brain, E.4    Jarcau, R.5    Cvitkovic, F.6
  • 44
    • 77952549994 scopus 로고    scopus 로고
    • Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice
    • Pfannenstiel LW, Lam SS, Emens LA, Jaffee EM, Armstrong TD. Paclitaxel enhances early dendritic cell maturation and function through TLR4 signaling in mice. Cell Immunol 2010;263:79-87.
    • (2010) Cell Immunol , vol.263 , pp. 79-87
    • Pfannenstiel, L.W.1    Lam, S.S.2    Emens, L.A.3    Jaffee, E.M.4    Armstrong, T.D.5
  • 45
    • 0035328683 scopus 로고    scopus 로고
    • Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor activity of a granulocyte-macrophage-colony stimulating factor-secreting whole-cell vaccine in HER-2/neu tolerized mice
    • Machiels JP, Reilly RT, Emens LA, Ercolini AM, Lei RY, Weintraub D, et al. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor activity of a granulocyte-macrophage-colony stimulating factor-secreting whole-cell vaccine in HER-2/neu tolerized mice. Cancer Res 2001; 61:3689-97.
    • (2001) Cancer Res , vol.61 , pp. 3689-3697
    • Machiels, J.P.1    Reilly, R.T.2    Emens, L.A.3    Ercolini, A.M.4    Lei, R.Y.5    Weintraub, D.6
  • 47
    • 1542472888 scopus 로고    scopus 로고
    • Toward a breast cancer vaccine: Work in progress
    • Emens LA, Jaffee EM. Toward a breast cancer vaccine: work in progress. Oncology 2003;17:1200-11.
    • (2003) Oncology , vol.17 , pp. 1200-1211
    • Emens, L.A.1    Jaffee, E.M.2
  • 48
    • 80052206741 scopus 로고    scopus 로고
    • Phase III multicenter trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastaticbreast cancer
    • Miles D, Roche H, Martin M, Perren TJ, Cameron DA, Glaspy J, et al. Phase III multicenter trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastaticbreast cancer. Oncologist 2011;16:1092-100.
    • (2011) Oncologist , vol.16 , pp. 1092-1100
    • Miles, D.1    Roche, H.2    Martin, M.3    Perren, T.J.4    Cameron, D.A.5    Glaspy, J.6
  • 49
    • 84864662070 scopus 로고    scopus 로고
    • Multipeptide immune response to cancer vaccine IMA901 after singledose cyclophosphamide associates with longer patient survival
    • Walter S, Weinschenk T, Stenzyl A, Zkrojowy R, Pluzanska A, Szczylik C, et al. Multipeptide immune response to cancer vaccine IMA901 after singledose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254-61.
    • (2012) Nat Med , vol.18 , pp. 1254-1261
    • Walter, S.1    Weinschenk, T.2    Stenzyl, A.3    Zkrojowy, R.4    Pluzanska, A.5    Szczylik, C.6
  • 50
    • 73349084990 scopus 로고    scopus 로고
    • Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: A chemotherapy dose-ranging factorial study of safety and immune activation
    • Emens LA, Asquith JM, Leatherman JM, Kobrin BJ, Petrik S, Laiko M, et al. Timed sequential treatment with cyclophosphamide, doxorubicin, and an allogeneic granulocyte-macrophage colony-stimulating factor-secreting breast tumor vaccine: a chemotherapy dose-ranging factorial study of safety and immune activation. J Clin Oncol 2009;27:5911-8.
    • (2009) J Clin Oncol , vol.27 , pp. 5911-5918
    • Emens, L.A.1    Asquith, J.M.2    Leatherman, J.M.3    Kobrin, B.J.4    Petrik, S.5    Laiko, M.6
  • 52
    • 80053161751 scopus 로고    scopus 로고
    • Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms
    • Mkrtichyan M, Najjar YG, Raulfs EC, Abdalla MY, Samara R, Rotem Yehudar R, et al. Anti-PD-1 synergizes with cyclophosphamide to induce potent anti-tumor vaccine effects through novel mechanisms. Eur J Immunol 2011;41:2977-86.
    • (2011) Eur J Immunol , vol.41 , pp. 2977-2986
    • Mkrtichyan, M.1    Najjar, Y.G.2    Raulfs, E.C.3    Abdalla, M.Y.4    Samara, R.5    Rotem Yehudar, R.6


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.